Cogent Biosciences, Inc.

COGT Nasdaq SEC CIK 1622229
Follow Cogent Biosciences Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$111.4M −37.7% vs same quarter last year
EPS, diluted −$0.59 −18% vs same quarter last year
Operating cash flow −$80.8M −25.7% vs same quarter last year
Operating income −$117.2M −40.6% vs same quarter last year
Net income by quarter
−$67.9M
−$72M
−$73.5M
−$80.9M
−$102.5M
−$97.4M
−$96.4M
−$111.4M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income10 fiscal years
  • Revenue
  • Net income
−$400M−$300M−$200M−$100M$0$100MFY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25-−$328.9M
FY24-−$255.9M
FY23-−$192.4M
FY22-−$140.2M
FY21-−$72.3M
FY20$7.9M−$74.8M
FY19$22.5M−$31.8M
FY18$9.7M−$34.5M
FY17$8.4M−$25.5M
FY16--
MarginsShare of revenue
  • Operating margin
  • Net margin
−1500%−1000%−500%0%FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25--
FY24--
FY23--
FY22--
FY21--
FY20−1044.3%−950.4%
FY19−143%−141.5%
FY18−369.9%−354.8%
FY17−312.8%−304.9%
FY16--
Free cash flowOperating cash flow minus capital expenditure
−$300M−$200M−$100M$0FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$266M
FY24−$208.4M
FY23−$156.4M
FY22−$125.5M
FY21−$60.5M
FY20-
FY19−$41.5M
FY18−$33M
FY17−$26.7M
FY16-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Cogent Biosciences
  • Healthcare median
−1000%−750%−500%−250%0%FY17FY19FY21FY23FY25
Show the numbers
YearCogent BiosciencesHealthcare median
FY25-−30.6%
FY24-−47%
FY23-−58%
FY22-−80.4%
FY21-−71.9%
FY20−950.4%−62.2%
FY19−141.5%−46.3%
FY18−354.8%−49.6%
FY17−304.9%−45.9%
FY16-−36%